ReviewFolia microbiologica2026
Therapeutic advances in the fight against microbial resistance: innovative strategies and future challenges.
Review in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial Resistance (AMR) is characterized by the reduced effectiveness of antibiotics due to the adaptation of microorganisms, which limits therapeutic options and increases the severity of infections. This paper aims to discuss therapeutic advances in combating AMR, highlighting innovative strategies, future challenges, and the importance of raising public awareness about the responsible use of antibiotics. This narrative review is based on studies from databases such as the National Library of Medicine, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Scopus, and the Virtual Health Library, using targeted descriptors. The findings emphasize the historical shift from the pre-antibiotic era, marked by high mortality rates, to the antibiotic era, now confronted by the escalating challenge of resistance. Notable innovative strategies include the use of light-based therapies and photosensitizing agents to eradicate bacteria, the application of antimicrobial gases such as nitric oxide and ozone to reduce bacterial loads, and the development of bioactive molecules and cutting-edge technologies aimed at directly targeting resistant pathogens. Advancing these novel therapies, along with raising public awareness about the responsible use of antibiotics, is crucial to curbing the threat of AMR and safeguarding global health.
Indexed as
Identifiers
41131219What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.